Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
PEL will explore the PLI scheme and apply if its beneficial.
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
Subscribe To Our Newsletter & Stay Updated
